uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in treating Huntington's disease. While the market cheered the news, the Adhishthana Principles paint a more cautious picture investors should not ignore.uniQure's Cycle So FaruniQure has had an eventful journey through its 18-phase Adhishthana cycle on the weekly charts. Now in Phase 17, it's worth revisiting how ...

CANADA - 2025/09/24: In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesUniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II trial. ((UniQure's Press Release, Sep 24, 2025)) This milestone marks the first therap ...

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. The Dow Jones Industrial Average declined 0.37% to 46,121.28, while the S&P 500 eased 0.3% to 6,637.97.These are the top stocks that gained the attention of retail traders and investors through the day:Alibaba Group Holding Ltd. BABAAlibaba’s stock surged by 8.19%, closing at $176.44. The stock reached an intraday high of $180.16 and a low of $162.80, with a 52-week range of $80.06 to $180.16. The r ...

Wednesday, Sept 24, 2025 The market fell today as it reacted to Fed Chair Jerome Powell’s speech on Tuesday. In it, Powell focused on market uncertainty and underlined stagflation. All the major indices closed lower. The oil and energy sectors continue to rise and emerge as the markets' best performers. Total debit and credit card spending per household has strengthened in the past few months. The S&P 500 was down 0.3%, and the tech-heavy Nasdaq closed 0.3% lower, still reeling from Tuesday’s low in ...

公司股价表现 - uniQure N V股价飙升至45.1美元 单日涨幅达230.16% 年高低点分别为51.19美元和4.45美元 成交量58,563,496股远超日均114万股的交易水平 [2] - SHF Holdings股价跃升至7.01美元 单日涨幅达115.03% 日高触及9.18美元 成交量29,808,900股显著高于日均851,200股的交易规模 [3] - Nushares ETF Trust旗下三只ETF价格均实现100%增长 NHYB收报25.01美元 NSCI收报25.03美元 NXUS收报25.02美元 均呈现交易量激增现象 [4] 公司重大进展 - uniQure实验性基因疗法成功治疗亨廷顿病 该突破性进展直接推动股价单日涨幅超240% [2][6] - SHF Holdings推出行业首个全托管大麻银行计划 为金融机构提供全面运营与合规外包服务 该创新金融服务推动股价大幅上涨 [3] 金融产品特征 - Nuveen高收益公司债券ETF提供高收益公司债多元化投资 exposure [4] - 证券化收入ETF聚焦证券化收入资产投资领域 [4] - Nuveen国际综合债券ETF覆盖国际综合债券投资标的 [4]

A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Skip to Main Content This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. These Stocks Moved the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More By Joe Woelfel, Elsa Ohlen, Mackenzie Tatananni and Connor Smith Share Resize Reprints Continue ...

Denmark's Orsted said on Wednesday it had resumed work on a U.S. offshore wind project after a federal judge on Monday ruled it could restart construction while the Trump administration's legal case t... ...